Cumberland Partners Ltd lowered its stake in Sanofi (NYSE:SNY) by 2.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,750 shares of the company’s stock after selling 750 shares during the period. Cumberland Partners Ltd’s holdings in Sanofi were worth $1,036,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in SNY. JFS Wealth Advisors LLC raised its position in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares in the last quarter. BlackRock Institutional Trust Company N.A. bought a new position in shares of Sanofi during the first quarter valued at about $175,000. Rehmann Capital Advisory Group raised its position in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock valued at $233,000 after buying an additional 26 shares in the last quarter. Flow Traders U.S. LLC raised its position in shares of Sanofi by 1.3% in the first quarter. Flow Traders U.S. LLC now owns 6,128 shares of the company’s stock valued at $246,000 after buying an additional 81 shares in the last quarter. Finally, Cypress Wealth Advisors LLC bought a new position in shares of Sanofi during the first quarter valued at about $247,000. 9.42% of the stock is owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE:SNY) traded up 0.50% during mid-day trading on Thursday, hitting $38.57. The stock had a trading volume of 2,606,995 shares. The stock’s 50-day moving average is $39.42 and its 200 day moving average is $40.63. Sanofi has a 1-year low of $37.41 and a 1-year high of $51.88. The firm has a market capitalization of $99.28 billion, a price-to-earnings ratio of 21.39 and a beta of 1.01.
Several research analysts recently issued reports on the company. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, June 6th. Citigroup Inc. reiterated a “neutral” rating on shares of Sanofi in a report on Tuesday, June 28th. Jefferies Group reiterated a “hold” rating on shares of Sanofi in a report on Wednesday, September 14th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Sanofi in a report on Thursday, September 15th. Finally, TheStreet upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Wednesday, July 27th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $60.50.
Sanofi Company Profile
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.